Centene Corporation (NYSE:CNC) Tightens Costs And Signals Near-Term Cash Flow Strength

Centene shows accelerating cash generation and clear technical momentum, positioning the company for continued valuation re-rating if operational discipline persists.

Recent News

April 28, 2026: Centene reported first-quarter 2026 results and raised full-year guidance. April 6, 2026: the company created two new executive leadership roles reporting to the CEO. February 6, 2026: Centene published 2025 results and issued 2026 guidance. April 2, 2026: two Centene subsidiaries received regulatory approval to combine operations in North Carolina. Early March 2026: Centene submitted proposed Medicaid program integrity reforms to federal regulators.

Technical Analysis

Directional indicators (ADX/DI+/DI-): ADX at 43.41 signals a very strong underlying trend; DI+ at 48.10 and rising while DI- at 11.02 and falling indicates clear bullish directional strength tied to upward price pressure and supports a near-term positive price bias.

MACD: MACD sits at 4.05, the MACD trend shows increasing momentum, and the MACD has crossed above its signal line (signal 2.57), which confirms bullish momentum expansion that aligns with the valuation gap implied below.

MRO: MRO reads 4.21 and trends higher, a positive value that indicates price sits modestly above the model target and implies a limited mean-reversion risk to the downside absent fresh catalysts; that constraint tempers immediate upside from current levels.

RSI and momentum: RSI at 61.52 and rising reflects constructive short-term momentum without extreme overextension; price sits above the 12-day EMA ($49.19) and well above the 50- and 200-day averages ($39.95 and $37.13), reinforcing upward price bias versus longer-term averages.

Price structure and volatility: Close at $55.33 lies just above the 1x Bollinger upper band ($54.54) but below the 2x band ($62.40), suggesting strength within a reasonable volatility band; super trend lower at $49.58 offers a nearby technical support level. Trading volume near 7.98M trades below the 10- and 200-day averages, implying current moves lack unusually high participation despite trend confirmation. Low 42-day and 52-week betas (0.37) indicate muted market sensitivity and lower expected directional volatility.

 


Fundamental Analysis

Profitability and margins: EBIT equals $2,263,000,000 and EBIT margin stands at 4.53%. EBIT margin QoQ changed -2.6387% while EBIT margin YoY changed 0.10243%. The EBIT margin sits below the industry peer mean and below the industry peer median, but above the industry peer low, indicating room to converge toward peer medians if cost controls persist.

Earnings and guidance: Adjusted diluted EPS for the quarter printed $3.37 versus an estimate of $2.13, a beat of $1.24 and an EPS surprise of 58.22%, reinforcing management’s ability to lift near-term profitability versus consensus expectations.

Cash flow and valuation signals: Operating cash flow reached $4,366,000,000 and free cash flow $4,166,000,000, producing a free cash flow yield of 21.95%, well above the industry peer mean; the enterprise multiple stands at 4.53, materially below the industry peer mean. Those cash-generation metrics drive the WMDST valuation: WMDST values the stock as under-valued on a free-cash-flow and enterprise-multiple basis.

Liquidity and leverage: Cash and short-term investments total $23,741,000,000 and the cash ratio equals 0.5929; total debt equals $16,371,000,000 with debt-to-equity 0.7640 (slightly below the industry peer mean). Interest coverage sits at 13.80, comfortably above the industry peer mean, signaling strong capacity to service debt despite a debt-to-EBITDA of 6.39.

Revenue and growth: Total revenue equals $49,944,000,000 with YoY revenue growth of 0.44% and revenue growth QoQ at 5.28571%. Reported net income totaled $1,541,000,000. Asset turnover equals 0.6325, above the industry peer mean, contributing to positive operational leverage even as some margin measures compress.

Valuation summary: High free cash flow yield, low enterprise multiple, and strong interest coverage underpin the WMDST valuation of under-valued; margin expansion and sustained cash conversion represent the primary pathways for the market to re-rate the stock.

MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2026-03-31
REPORT DATE: 2026-04-28
NEXT REPORT DATE: 2026-07-28
CASH FLOW  Begin Period Cash Flow 18.0 B
 Operating Cash Flow 4.4 B
 Capital Expenditures -200.00 M
 Change In Working Capital 2.5 B
 Dividends Paid
 Cash Flow Delta 3.4 B
 End Period Cash Flow 21.4 B
 
INCOME STATEMENT REVENUE
 Total Revenue 49.9 B
 Forward Revenue 4.5 B
COSTS
 Cost Of Revenue 44.4 B
 Depreciation 134.0 M
 Depreciation and Amortization 300.0 M
 Research and Development
 Total Operating Expenses 48.1 B
PROFITABILITY
 Gross Profit 5.6 B
 EBITDA 2.6 B
 EBIT 2.3 B
 Operating Income 1.9 B
 Interest Income
 Interest Expense 164.0 M
 Net Interest Income -164.00 M
 Income Before Tax 2.1 B
 Tax Provision 560.0 M
 Tax Rate 26.679 %
 Net Income 1.5 B
 Net Income From Continuing Operations 1.5 B
EARNINGS
 EPS Estimate 2.13
 EPS Actual 3.37
 EPS Difference 1.24
 EPS Surprise 58.216 %
 Forward EPS 1.12
 
BALANCE SHEET ASSETS
 Total Assets 81.2 B
 Intangible Assets 15.2 B
 Net Tangible Assets 6.2 B
 Total Current Assets 45.0 B
 Cash and Short-Term Investments 23.7 B
 Cash 21.3 B
 Net Receivables 19.4 B
 Inventory
 Long-Term Investments 2.3 B
LIABILITIES
 Accounts Payable 16.8 B
 Short-Term Debt 63.0 M
 Total Current Liabilities 40.0 B
 Net Debt
 Total Debt 16.4 B
 Total Liabilities 59.6 B
EQUITY
 Total Equity 21.4 B
 Retained Earnings 10.2 B
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share 43.57
 Shares Outstanding 493.771 M
 Revenue Per-Share 101.56
VALUATION
 Market Capitalization 19.0 B
 Enterprise Value 11.6 B
 Enterprise Multiple 4.529
Enterprise Multiple QoQ -126.166 %
Enterprise Multiple YoY -67.7 %
Enterprise Multiple IPRWA high: 159.017
median: 41.816
mean: 38.688
low: 10.495
CNC: 4.529
 EV/R 0.232
CAPITAL STRUCTURE
 Asset To Equity 3.788
 Asset To Liability 1.361
 Debt To Capital 0.433
 Debt To Assets 0.202
Debt To Assets QoQ -14.777 %
Debt To Assets YoY -4.176 %
Debt To Assets IPRWA high: 0.481
mean: 0.275
median: 0.253
CNC: 0.202
low: 0.154
 Debt To Equity 0.764
Debt To Equity QoQ -16.062 %
Debt To Equity YoY 16.425 %
Debt To Equity IPRWA high: 1.595
mean: 0.851
CNC: 0.764
median: 0.753
low: 0.279
PRICE-BASED VALUATION
 Price To Book (P/B) 0.886
Price To Book QoQ -12.786 %
Price To Book YoY -18.264 %
Price To Book IPRWA high: 6.333
mean: 1.846
median: 1.563
low: 1.082
CNC: 0.886
 Price To Earnings (P/E) 11.452
Price To Earnings QoQ -133.072 %
Price To Earnings YoY -45.381 %
Price To Earnings IPRWA high: 165.793
mean: 45.505
median: 35.418
low: 19.261
CNC: 11.452
 PE/G Ratio -0.03
 Price To Sales (P/S) 0.38
Price To Sales QoQ -6.753 %
Price To Sales YoY -41.438 %
Price To Sales IPRWA high: 8.255
mean: 2.689
median: 1.367
low: 0.61
CNC: 0.38
FORWARD MULTIPLES
Forward P/E 38.694
Forward PE/G -0.101
Forward P/S 4.737
EFFICIENCY OPERATIONAL
 Operating Leverage -600.746
ASSET & SALES
 Asset Turnover Ratio 0.633
Asset Turnover Ratio QoQ 1.019 %
Asset Turnover Ratio YoY 14.977 %
Asset Turnover Ratio IPRWA high: 1.061
CNC: 0.633
mean: 0.403
median: 0.397
low: 0.15
 Receivables Turnover 2.661
Receivables Turnover Ratio QoQ 10.297 %
Receivables Turnover Ratio YoY 20.312 %
Receivables Turnover Ratio IPRWA high: 9.342
mean: 3.688
CNC: 2.661
median: 2.236
low: 0.645
 Inventory Turnover
Inventory Turnover Ratio QoQ
Inventory Turnover Ratio YoY
Inventory Turnover Ratio IPRWA
 Days Sales Outstanding (DSO) 34.285
CASH CYCLE
 Cash Conversion Cycle Days (CCC) 4.878
Cash Conversion Cycle Days QoQ
Cash Conversion Cycle Days YoY
Cash Conversion Cycle Days IPRWA high: 101.8
mean: 21.907
median: 19.637
CNC: 4.878
low: -49.905
CAPITAL DEPLOYMENT
 Cash Conversion Ratio 10.102
 CapEx To Revenue -0.004
 CapEx To Depreciation -1.493
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital 37.7 B
 Net Invested Capital 37.8 B
 Invested Capital 37.8 B
 Net Tangible Assets 6.2 B
 Net Working Capital 4.9 B
LIQUIDITY
 Cash Ratio 0.593
 Current Ratio 1.123
Current Ratio QoQ 2.122 %
Current Ratio YoY 1.067 %
Current Ratio IPRWA high: 1.711
CNC: 1.123
mean: 0.97
median: 0.866
low: 0.834
 Quick Ratio
Quick Ratio QoQ
Quick Ratio YoY
Quick Ratio IPRWA
COVERAGE & LEVERAGE
 Debt To EBITDA 6.387
 Cost Of Debt 0.696 %
 Interest Coverage Ratio 13.799
Interest Coverage Ratio QoQ -268.596 %
Interest Coverage Ratio YoY 22.432 %
Interest Coverage Ratio IPRWA high: 17.352
CNC: 13.799
mean: 6.314
median: 6.088
low: 1.286
 Operating Cash Flow Ratio 0.093
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO) 29.407
DIVIDENDS
 Dividend Coverage Ratio
 Dividend Payout Ratio
 Dividend Rate
 Dividend Yield
PERFORMANCE GROWTH
 Asset Growth Rate 5.77 %
 Revenue Growth 0.44 %
Revenue Growth QoQ 528.571 %
Revenue Growth YoY -96.912 %
Revenue Growth IPRWA high: 42.726 %
CNC: 0.44 %
mean: -0.765 %
median: -2.07 %
low: -7.833 %
 Earnings Growth -383.193 %
Earnings Growth QoQ 13.371 %
Earnings Growth YoY -245.978 %
Earnings Growth IPRWA high: 428.571 %
mean: 51.451 %
median: -3.589 %
low: -360.354 %
CNC: -383.193 %
MARGINS
 Gross Margin 11.128 %
Gross Margin QoQ 124.31 %
Gross Margin YoY -0.269 %
Gross Margin IPRWA high: 96.442 %
median: 32.815 %
mean: 31.978 %
CNC: 11.128 %
low: 9.466 %
 EBIT Margin 4.531 %
EBIT Margin QoQ -263.87 %
EBIT Margin YoY 10.243 %
EBIT Margin IPRWA high: 23.127 %
mean: 8.192 %
median: 5.303 %
CNC: 4.531 %
low: 0.769 %
 Return On Sales (ROS) 3.726 %
Return On Sales QoQ -250.363 %
Return On Sales YoY -9.343 %
Return On Sales IPRWA high: 37.538 %
median: 12.863 %
mean: 10.527 %
CNC: 3.726 %
low: 1.255 %
CASH FLOW
 Free Cash Flow (FCF) 4.2 B
 Free Cash Flow Yield 21.951 %
Free Cash Flow Yield QoQ 1886.516 %
Free Cash Flow Yield YoY 382.97 %
Free Cash Flow Yield IPRWA CNC: 21.951 %
high: 13.5 %
median: 3.426 %
mean: 3.077 %
low: -0.71 %
 Free Cash Growth 1759.821 %
Free Cash Growth QoQ -2287.825 %
Free Cash Growth YoY -716.27 %
Free Cash Growth IPRWA CNC: 1759.821 %
high: 298.093 %
median: 2.874 %
mean: -24.003 %
low: -455.219 %
 Free Cash To Net Income 2.703
 Cash Flow Margin 7.456 %
 Cash Flow To Earnings 2.417
VALUE & RETURNS
 Economic Value Added 0.03
 Return On Assets (ROA) 1.952 %
Return On Assets QoQ -240.837 %
Return On Assets YoY 26.18 %
Return On Assets IPRWA high: 4.991 %
CNC: 1.952 %
mean: 1.718 %
median: 1.426 %
low: 0.074 %
 Return On Capital Employed (ROCE) 5.502 %
 Return On Equity (ROE) 0.072
Return On Equity QoQ -230.337 %
Return On Equity YoY 53.152 %
Return On Equity IPRWA high: 0.146
CNC: 0.072
mean: 0.047
median: 0.039
low: 0.002
 DuPont ROE 7.447 %
 Return On Invested Capital (ROIC) 4.39 %
Return On Invested Capital QoQ -267.302 %
Return On Invested Capital YoY 40.705 %
Return On Invested Capital IPRWA high: 7.1 %
CNC: 4.39 %
mean: 3.693 %
median: 2.946 %
low: 0.635 %

Six-Week Outlook

Momentum and trend strength favor a bullish near-term profile: rising DI+, an ADX above 40, and a bullish MACD crossover support continued upside in the coming six weeks, while price above the 12-day EMA and near-term support at $49.58 provide reference levels for technical traction. Countervailing risk stems from the positive MRO, which signals modest mean-reversion pressure since price sits above the model target; low trading volume versus longer averages suggests moves could remain narrow until catalysts (earnings cadence, regulatory updates, or material contract news) trigger higher participation. Given the current technical alignment and the under-valued cash-flow profile, expect a bias toward consolidation with episodic upside on catalyst days, and watch for any loss of DI+ momentum or a declining ADX as the first sign that that bullish setup weakens.

About Centene Corporation

Centene Corporation (NYSE:CNC) delivers comprehensive healthcare services, primarily targeting under-insured and uninsured populations across the United States. Established in 1984 and based in St. Louis, Missouri, Centene develops a wide array of health plans through its Medicaid, Medicare, and Commercial segments. The Medicaid segment offers expanded health plans, children’s health insurance programs, and long-term services. In the Medicare segment, Centene addresses the needs of seniors with special needs plans, Medicare supplements, and prescription drug plans. The Commercial segment provides marketplace insurance products for individuals and businesses, ensuring extensive access to healthcare services. Centene actively participates in government healthcare contracts, including the TRICARE program for military families, highlighting its dedication to diverse communities. The company also manages clinical healthcare services, pharmacies, and provides dental and speech therapy, promoting a holistic healthcare approach. By collaborating with primary and specialty care physicians, hospitals, and ancillary providers, Centene aims to deliver personalized, high-quality care to millions of Americans, emphasizing innovation and community well-being.



© 2026 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.